Global Diabetic Neuropathy Treatment Market Report and Forecast 2024-2032

Global Diabetic Neuropathy Treatment Market Outlook

The global diabetic neuropathy treatment market is driven by the rising number of hyperglycaemia cases, which was nearly 569.59 million in 2023. The prevalence of the hyperglycaemia is likely to grow at a CAGR of 3% during the forecast period of 2024-2032 to reach approximately 743.19 million cases by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Introduction

Diabetic neuropathy is a condition that causes nerve damage in people with diabetes. Nerves are damaged by high blood sugar in diabetics, resulting in diabetic neuropathy. 

Legs and feet are the most severely affected body parts in this condition. 

There are also symptoms associated with neuropathy, such as pain and numbness, depending on the nerves affected, such as peripheral nerves, autonomic nerves, proximal nerves, and focal nerves. 

Following are the different types of diabetic neuropathy:

• Peripheral Neuropathy- Affects legs and feet.

• Autonomic Neuropathy- Affects the digestive system, primarily the stomach.

• Proximal Neuropathy- Affects buttocks and thighs.

Worldwide, diabetes treatment is considered a top priority. It is not possible to cure neuropathic changes or provide pain relief with a single treatment. Various approaches are used to manage diabetic neuropathy, including intensive glucose control, treatment of risk factors, and treatment based on pathogenetic mechanisms.

The rapidly rising number of diabetic neuropathies and increased awareness in the next few years will compel major companies to launch new products. Thus, key players in the market are developing technologically advanced products to gain a competitive edge.

According to the global diabetic neuropathy treatment market research report, the market can be categorised into the following segments: 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Disease Type

• Peripheral Neuropathy

• Autonomic Neuropathy

• Proximal Neuropathy

• Focal Neuropathy

Market Breakup by Treatment Method

• Drugs
  • Analgesics
  • Antidepressant
  • Anticonvulsants
  • Others
• Transcutaneous Electrical Nerve Stimulation (TENS)

• Non-Steroidal Anti-Inflammatory Drugs

• Others

Diabetic Neuropathy Treatment Market Breakup by End-User

• Hospitals And Clinics

• Retail Pharmacy

• Online Pharmacy

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Prevalence of Diabetes to Drive the Diabetic Neuropathy Treatment Market Growth

The steep rise in diabetes cases will impact the growth of the market during the forecast period. The complications related to diabetes, cardiovascular diseases, obesity, and other complications related to glucose control contribute to neuropathy development. This includes the development of new products by manufacturers that are effective at treating neuropathy. 

Additionally, increased urbanization is causing unhealthy lifestyles like unhealthy food consumption, sedentary living, and others that adversely affect the market growth.

Other factors driving the growth of the diabetic neuropathy treatment market include ageing population, growing health care facilities, and increasing health care costs. 

Market Growth to be Hindered by the High Price of the Product and the Availability of Alternatives for Diabetic Neuropathy

Diabetes neuropathy drugs are becoming increasingly expensive, and alternative treatments for the condition are also available readily available. These factors are hindering the growth of the global market. 

Availability of alternative treatments, such as radiotherapy and physical therapy, that may improve patient outcomes, is also obstructing the growth of the market. Other factors that could hamper the market growth include regulations, product recalls, and FDA approval delays.

Regional Outlook for the Diabetic Neuropathy Treatment Market

The increasing diabetes prevalence and incidence cases make North America a major regional market. Various factors contribute to the growth of the market, such as early adoption of drugs, availability of advanced therapies, and the availability of combination drugs. 

It is estimated that the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to the high prevalence of diabetes, obesity, and cardiac arrhythmia-related issues, and government support for healthcare awareness and research activities.

Therapeutic Landscape

People with diabetes can be affected by diabetic neuropathy, a chronic debilitating condition. The objective assessment of diabetic neuropathy makes it difficult to diagnose and evaluate in clinical trials. Currently, there is no treatment available to prevent or reverse neuropathy or to relieve pain completely. 

Diabetic neuropathy could be treated with Nav 1.7 antagonists, calcium channel blockers, anti-NGF antibodies, and angiotensin II type 2 receptor antagonists.

As part of its neuropathic pain treatment program, Novartis AG introduced Tegerton (carbamazepine), a new epilepsy drug designed to reduce nerve impulses that cause pain in diabetics. 

Nucynta ER, a pain reliever derived from opioids, used to treat diabetes-induced nerve damage, was also launched by Janssen Pharmaceuticals. 

Among the recommended treatment options for diabetic neuropathy, there are antidepressants like amitriptyline and duloxetine as well as topical agents like gabapentin and pregabalin analogues and opioids for pain relief in neuropathy. 

In order to alleviate pain and improve quality of life associated with diabetic neuropathy, more research is needed on the most effective drugs or combinations. 

Clinical Trials

In current therapies, sensory deficits and aetiology are not addressed, so there is an unmet demand for treatment options that target the natural course of the condition. 

The outcomes of recent randomized controlled trials show that some of these pathological treatments improve neuropathic endpoints clinically. Patients with neuropathic pain remain undertreated with effective analgesic monotherapy as limited number of patients able to achieve clinically meaningful results. 

New pharmaceutical approaches have been expanded due to increased knowledge of neurobiology and phenotypic profiling of neuropathic pain. 

A number of promising molecular structures are in clinical development, which will soon improve our therapeutic arsenal of diabetic neuropathy treatments. 

In diabetic neuropathy, the disease progresses over time. Medication and lifestyle changes can alleviate this condition. Medications that control diabetes are the most effective in slowing the onset of complications caused by diabetes. 

The FDA has approved these drugs for treating diabetic neuropathy: 

• anticonvulsant Lyrica (pregabalin)

• antidepressant Cymbalta (duloxetine)

• opioid Nucinta (tapentadol)

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global diabetic neuropathy treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

• Novartis AG

• Pfizer Inc.

• Glenmark Pharmaceuticals Ltd.

• Eli Lilly and Company

• Abbott Laboratories

• F. Hoffmann-La Roche Ltd

• Johnson & Johnson

• GlaxoSmithKline Plc

• Lupin Ltd

• Depomed, Inc

• Astellas Pharma Inc

• Meda Pharma GmBH & Co. KG

Key Highlights of the Report